|
 The European Commission approved the injection for people with
previously untreated and relapsed/refractory forms of the disease.
"MabThera SC provides patients with significantly faster treatment
administration and the opportunity to enjoy more time outside the
clinical setting compared to intravenous delivery of the medicine,"
Chief Medical Officer Sandra Horning said.
(Reporting by Brenna Hughes Neghaiwi; Editing by Michael Shields)
[© 2016 Thomson Reuters. All rights
reserved.] Copyright 2016 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
